Enlivex Therapeutics Ltd. (ENLV) Stock Forecast
ENLV analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $80.00 average of analyst targets
- Upside to target
- +38,924.4% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.28
- 52-week range
- $0.20 – $18.15
ENLV analyst ratings
1 analystsNumber of analysts at each rating.
ENLV price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ENLV earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.28 | −$0.28 | −$0.28 | −$1.35 | +79.3% | 1 |
| Current fiscal year (2026) | −$1.15 | −$1.15 | −$1.15 | $382.20 | −100.3% | 1 |
| Next fiscal year (2027) | −$0.21 | −$0.21 | −$0.21 | −$1.15 | +81.7% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ENLV revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
ENLV EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ENLV EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.30 | −$0.30 | −$0.30 | −$0.30 | −$0.28 | −6.7% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.20 | −$1.20 | −$1.20 | −$1.20 | −$1.15 | −4.2% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.35 | −$1.35 | −$1.35 | −$1.35 | −$0.21 | −84.4% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ENLV earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ENLV beat in 6 of 12.
What analysts expect from ENLV
1 analysts cover Enlivex Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $80.00, 38,924.4% above the latest close of $0.20. Analysts expect earnings of −$1.15 per share for 2026, −100.3% from a year earlier. For 2027 the average estimate is −$0.21 per share. Enlivex Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: ENLV income statement, ENLV key metrics, ENLV chart. See the ENLV stock overview for the latest quote and news.
ENLV forecast FAQ
What is Enlivex Therapeutics's price target?
The average analyst price target for Enlivex Therapeutics is $80.00, 38,924.4% above the latest close of $0.20.
Is Enlivex Therapeutics a buy, hold or sell?
Of 1 analysts covering Enlivex Therapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Enlivex Therapeutics's EPS forecast?
Analysts forecast −$1.15 per share for 2026 (range −$1.15 to −$1.15); for 2027 the estimate is −$0.21.
When does Enlivex Therapeutics report earnings?
Enlivex Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.28.
Does Enlivex Therapeutics usually beat earnings estimates?
Enlivex Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.